A virtual disruptive late clinical-stage novel ophthalmology drug platform
Theialife is aiming to reduce myopic progression in children & build a portfolio of innovative ophthalmic range for vision threatening complications. Bringing the “discovery” back to “drug-discovery” in ophthalmology.
Because every eye deserves sight.
For the future of every childs vision.
LEAD PRODUCT CANDIDATES
Our late-stage phase 3 drug – 7MX – provides unique therapeutic options for millions of diagnosed but untreated or undertreated myopia in children.
Theialife is featured on the front cover of the coveted British Journal of Ophthalmology
To learn more about the groundbreaking benefits of 7-Methyl-Xanthine in the use of Myopia control and treatment in children, The British journal of Ophthalmology published a peer-reviewed article.
Theialife is featured in the International Journal of Ophthalmology
Featured in a second peer-reviewed publication in the International Journal of Ophthalmology. Read our latest article on the “Role of 7-methylxanthine in myopia prevention and control: a mini-review”